Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Curtis A. Lachowiez, Vishvaas I. Ravikumar, Jad Othman, Jenny O'Nions, Daniel T. Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N. Saultz, Jeffrey W. Tyner, Richard Dillon, Joshua F. Zeidner, Daniel A. Pollyea

Research output: Contribution to journalArticlepeer-review

Abstract

The European LeukemiaNet 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates reclassification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.

Original languageEnglish (US)
Pages (from-to)2788-2792
Number of pages5
JournalBlood
Volume144
Issue number26
DOIs
StatePublished - Dec 26 2024

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML'. Together they form a unique fingerprint.

Cite this